Skip Navigation



International Immunology Advance Access published online on December 21, 2007
International Immunology, doi:10.1093/intimm/dxm133
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/2/165    most recent
dxm133v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mihaylova, N.
Right arrow Articles by Vassilev, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mihaylova, N.
Right arrow Articles by Vassilev, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Japanese Society for Immunology. 2007. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc{gamma}IIb receptor

Nikolina Mihaylova1, Elisaveta Voynova1, Andrey Tchorbanov1, Maria Nikolova2, Antoaneta Michova2, Todor Todorov3, Luba Srebreva4, Hristo Taskov2 and Tchavdar Vassilev1

1 Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria
2 Central Laboratory of Immunology, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
3 Department of Pathology, Sofia Medical School, Sofia, Bulgaria
4 Department of Gene Regulation, Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, Bulgaria

Correspondence to: Correspondence to: T. Vassilev, Stefan Angelov Institute of Microbiology, Academy G. Bonchev Street, Block 26, 1113 Sofia, Bulgaria. E-mail: vassilev{at}microbio.bas.bg

The presently used approaches to silence autoreactive disease-associated B cells act indiscriminately and more specific therapies are obviously needed. In the present study, we analyze the ability of a chimeric antibody to suppress selectively pathological autoreactive B-lymphocytes in lupus-prone mice by cross-linking their surface Ig receptors with the inhibitory IgG Fc{gamma}RIIb receptors. The chimera was constructed by coupling an immunodominant mouse Histone 1 peptide to a rat monoclonal anti-mouse CD32 (Fc{gamma}RIIb) antibody. The administration of these chimeric molecules to MRL/lpr mice with initial and with full-blown disease resulted in the reduction of the levels of IgG anti-Histone 1 antibodies, of the albuminuria levels, of the size of lymphoid organs and in prevention of the development of skin lesions. The observed effect was limited to lupus-associated B cells only, as the treatment did not decrease the IgG antibody response to an administered foreign antigen. This study demonstrates the possibility to silence selectively autoreactive B cells and to delay the progression of an autoimmune disease using chimeric antibody molecules.

Keywords: auto-antibodies, Fc{gamma}RIIb, Histone 1, lupus

Transmitting editor: S. Izui

Received 6 July 2006, accepted 5 November 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.